Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Reports

Sialic Acid-Fibronectin–negative and CD-44–positive Pancreatic Cancer Has a Poor Prognosis Due To Epithelial-Mesenchymal Transition

TAKESHI GOCHO, HIROSHI TAKEYAMA, YOSHINOBU MANOME, TOMOYUKI TANAKA, MICHINORI MATSUMOTO, TARO SAKAMOTO, TAKAAKI YAMASHITA and TORU IKEGAMI
Anticancer Research January 2026, 46 (1) 515-530; DOI: https://doi.org/10.21873/anticanres.17965
TAKESHI GOCHO
1Department of Hepatobiliary and Pancreatic Surgery, Jikei University School of Medicine, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI TAKEYAMA
2Department of Breast, Thyroid, Endocrine Surgery, Jikei University School of Medicine, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: takeyama{at}jikei.ac.jp
YOSHINOBU MANOME
3Institute of DNA Sciences, Yokohama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMOYUKI TANAKA
1Department of Hepatobiliary and Pancreatic Surgery, Jikei University School of Medicine, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHINORI MATSUMOTO
1Department of Hepatobiliary and Pancreatic Surgery, Jikei University School of Medicine, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TARO SAKAMOTO
1Department of Hepatobiliary and Pancreatic Surgery, Jikei University School of Medicine, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAAKI YAMASHITA
2Department of Breast, Thyroid, Endocrine Surgery, Jikei University School of Medicine, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TORU IKEGAMI
1Department of Hepatobiliary and Pancreatic Surgery, Jikei University School of Medicine, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Increases in cellular fibronectin (C-FN) in the stroma have been identified as one of the factors that induce epithelial-mesenchymal transition (EMT), which enhances cancer malignancy. We measured blood levels of sialic acid–fibronectin (S-FN), a form of C-FN secreted by pancreatic ductal adenocarcinoma (PDAC), along with total C-FN, to investigate whether their secretion is associated with tumor progression and EMT.

Patients and Methods: Total blood C-FN and S-FN levels were measured using ELISA, and immunostaining for vimentin, CD-44, and cytokeratin was performed on 13 pancreatic tumors to examine their relevance to EMT.

Results: Four of 11 PDAC cases (36.4%) were blood S-FN-positive. Vimentin-positive cells (VPCs) in the stroma, which indicate an increase in cancer-associated fibroblasts (CAFs), numbered fewer than 50 per field of view in four of four S-FN–positive cases and three of seven S-FN–negative cases. These patients demonstrated partial therapeutic effects of chemoradiotherapy. In contrast, four of seven S-FN-negative cases had more than 50 VPCs and showed extensive fibrous growths in the stroma. No therapeutic effects were observed, and the prognoses were poor. In the four stage IV cases with metastases at the time of presentation, 80-90% of PDAC cells expressed CD-44 receptors, an EMT-related factor. CD-44 positivity was also found in CAFs around the PDCA, indicating cross-talk between PDAC and CAFs via CD-44.

Conclusion: In blood S-FN–negative cases with depleted autocrine FN, therapeutic effects were reduced owing to the increased presence of VPCs, presumed to be CAFs induced by EMT. CD-44–positive PDAC cells, which are partially EMT cells, are prone to early distant metastasis.

Keywords:
  • Pancreatic ductal adenocarcinoma
  • sialic acid-fibronectin
  • cellular fibronectin
  • epithelial-mesenchymal transition
  • cancer-associated fibroblasts
  • Received October 2, 2025.
  • Revision received October 17, 2025.
  • Accepted November 3, 2025.
  • Copyright © 2026 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 46 (1)
Anticancer Research
Vol. 46, Issue 1
January 2026
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Ed Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Sialic Acid-Fibronectin–negative and CD-44–positive Pancreatic Cancer Has a Poor Prognosis Due To Epithelial-Mesenchymal Transition
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Sialic Acid-Fibronectin–negative and CD-44–positive Pancreatic Cancer Has a Poor Prognosis Due To Epithelial-Mesenchymal Transition
TAKESHI GOCHO, HIROSHI TAKEYAMA, YOSHINOBU MANOME, TOMOYUKI TANAKA, MICHINORI MATSUMOTO, TARO SAKAMOTO, TAKAAKI YAMASHITA, TORU IKEGAMI
Anticancer Research Jan 2026, 46 (1) 515-530; DOI: 10.21873/anticanres.17965

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Sialic Acid-Fibronectin–negative and CD-44–positive Pancreatic Cancer Has a Poor Prognosis Due To Epithelial-Mesenchymal Transition
TAKESHI GOCHO, HIROSHI TAKEYAMA, YOSHINOBU MANOME, TOMOYUKI TANAKA, MICHINORI MATSUMOTO, TARO SAKAMOTO, TAKAAKI YAMASHITA, TORU IKEGAMI
Anticancer Research Jan 2026, 46 (1) 515-530; DOI: 10.21873/anticanres.17965
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Patient and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Individualized Estimated Glomerular Filtration Rate-based Renal Function Association With Cisplatin Treatment Completion in Cervical Cancer
  • Real-world Outcomes of Postoperative Management for Sentinel Lymph Node-positive Breast Cancer Without Intraoperative Assessment: A Single-institution Retrospective Study
  • TTF-1 Expression and Efficacy of Platinum and Pemetrexed Plus Pembrolizumab in Advanced Lung Adenocarcinoma
Show more Clinical Reports

Keywords

  • Pancreatic ductal adenocarcinoma
  • sialic acid-fibronectin
  • cellular fibronectin
  • epithelial-mesenchymal transition
  • cancer-associated fibroblasts
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire